Editorial on immune checkpoint inhibitors in the treatment of hepatocellular carcinoma

References

• 1. Robinson MW, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol. Immunol. 13(3), 267–276 (2016).
  Medline CASGoogle Scholar
• 2. Franzin R, Netti GS, Spadaccino F et al. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand? Front. Immunol. 11, 574271 (2020).
  Medline CASGoogle Scholar
• 3. Finn RS, Qin S, Ikeda M et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382(20), 1894–1905 (2020).
  Medline CASGoogle Scholar
• 4. Abou-Alfa GK, Lau G, Kudo M et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence 1(8), EVIDoa2100070 (2022).
  Google Scholar
• 5. Reig M, Forner A, Rimola J et al. BCLC strategy for prognosis prediction and treatment recommendation: ghe 2022 update. J. Hepatol. 76(3), 681–693 (2022).
  MedlineGoogle Scholar
• 6. Kudo M, Matilla A, Santoro A et al. CheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child–Pugh B cirrhosis. J. Hepatol. 75(3), 600–609 (2021).
  Medline CASGoogle Scholar
• 7. Finn RS, Ryoo BY, Merle P et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J. Clin. Oncol. 38(3), 193–202 (2020).
  Medline CASGoogle Scholar
• 8. Han JW, Park SH. Advances in immune checkpoint inhibitors for hepatocellular carcinoma. J. Liver Cancer 21(2), 139–145 (2021).
  MedlineGoogle Scholar
• 9. Llovet JM, De Baere T, Kulik L et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18(5), 293–313 (2021).
  Medline CASGoogle Scholar
• 10. Xie L, Meng Z. Immunomodulatory effect of locoregional therapy in the tumor microenvironment. Mol. Ther. 31(4), 951–969 (2023).
  Medline CASGoogle Scholar
• 11. Friedman D, Baird JR, Young KH et al. Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma. Hepatol. Res. 47(7), 702–714 (2017).
  Medline CASGoogle Scholar
• 12. Chen L, Zhang R, Lin Z et al. Radiation therapy in the era of immune treatment for hepatocellular carcinoma. Front. Immunol. 14, 1100079 (2023).
  Medline CASGoogle Scholar
• 13. Ho WJ, Zhu Q, Durham J et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat. Cancer 2(9), 891–903 (2021).
  Medline CASGoogle Scholar
• 14. Zhang W, Hu B, Han J et al. Surgery after conversion therapy with PD-1 inhibitors plus tyrosine kinase inhibitors are effective and safe for advanced hepatocellular carcinoma: a pilot study of ten patients. Front Oncol. 11, 747950 (2021).
  Medline CASGoogle Scholar
• 15. Zhu XD, Huang C, Shen YH et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer 10(4), 320–329 (2021).
  Medline CASGoogle Scholar
• 16. Kaseb AO, Hasanov E, Cao HST et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 7(3), 208–218 (2022).
  MedlineGoogle Scholar
• 17. De Lorenzo S, Tovoli F, Trevisani F. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in patients with hepatocellular carcinoma. Cancers (Basel) 14(19), (2022).
  Google Scholar
• 18. Ang C, Klempner SJ, Ali SM et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget 10(40), 4018–4025 (2019).
  MedlineGoogle Scholar
• 19. Weiss SA, Sznol M. Resistance mechanisms to checkpoint inhibitors. Curr. Opin. Immunol. 69, 47–55 (2021).
  Medline CASGoogle Scholar